Dasatinib

Name: Dasatinib
Brand: Selleck Chemicals
SKU: S1021
Rating: 5 (266 reviews)

For research use only.

Catalog No.S1021 Synonyms: BMS-354825

266 publications

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Selleck's Dasatinib has been cited by 266 publications

Cell Stem Cell, 2020, 10;S1934-5909(20)30144-2

PubMed: 32413332 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Immunol, 2018, 19(6):561-570

PubMed: 29777213 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Nat Med, 2017, 23(3):291-300

PubMed: 28191885 ( click the link to review the publication )

Nat Med, 2017, 23(12):1424-1435

PubMed: 29131160 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Nat Genet, 2014, 46(2):166-70

PubMed: 24413734 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Blood, 2020, 8 pii: blood

PubMed: 32270193 ( click the link to review the publication )

Mol Cell, 2020, 7;S1097-2765(20)30269-0

PubMed: 32416067 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(4):1879-1895

PubMed: 31874105 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Neuro Oncol, 2020, 15;22(4):493-504

PubMed: 31883012 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, 30 pii: canres

PubMed: 32354737 ( click the link to review the publication )

Cell Rep, 2020, 24;30(12):3951-3963 e4

PubMed: 32209458 ( click the link to review the publication )

Cell Rep, 2020, 30(3):793-806

PubMed: 31968254 ( click the link to review the publication )

Oncogene, 2020, 39(20):3980-3996

PubMed: 32238881 ( click the link to review the publication )

Oncogene, 2020, 39(2):308-321

PubMed: 31477830 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )
Oncogene, 2020, 39(20):4045-4060

PubMed: 32214198 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 25;12(5)

PubMed: 32344828 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 31;12(4) pii: E841

PubMed: 32244515 ( click the link to review the publication )

Cancers (Basel), 2020, 26;12(4)

PubMed: 32224911 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Breast Cancer Res, 2020, 15;22(1):37

PubMed: 32295603 ( click the link to review the publication )

Cell Death Discov, 2020, 15;6:36

PubMed: 32435511 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Microb Cell Fact, 2020, 20;19(1):74

PubMed: 32197603 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )

Biochem Pharmacol, 2020, 30;177:113941

PubMed: 32240650 ( click the link to review the publication )

Sci Rep, 2020, 6;10(1):4211

PubMed: 32144278 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Breast Cancer Res Treat, 2020, 179(2):337-347

PubMed: 31655920 ( click the link to review the publication )

Cell Signal, 2020, 70:109574

PubMed: 32084531 ( click the link to review the publication )

Molecules, 2020, 8;25(9) pii: E2220

PubMed: 32397330 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 9

PubMed: 32268657 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31704808 ( click the link to review the publication )
Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Am J Respir Crit Care Med, 2019, 101164/rccm201902-0451OC

PubMed: 31738079 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1515

PubMed: 30944303 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2309

PubMed: 31857430 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(16):5038-5048

PubMed: 31182436 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.215939

PubMed: 31289206 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cancer Res, 2019, 79(13):3306-3319

PubMed: 31101761 ( click the link to review the publication )

Theranostics, 2019, 9(7):1952-1964

PubMed: 31037149 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Oncogene, 2019, 38(12):2135-2150

PubMed: 30459358 ( click the link to review the publication )

Stem Cell Reports, 2019, 10.1016/j.stemcr.2019.08.005

PubMed: 31522974 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):567-577

PubMed: 31474759 ( click the link to review the publication )

J Clin Med, 2019, 8(8)

PubMed: 31382448 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0449

PubMed: 31744897 ( click the link to review the publication )

J Physiol, 2019, 597(6):1627-1642

PubMed: 30488437 ( click the link to review the publication )

Mol Biol Cell, 2019, 30(9):1108-1117

PubMed: 30785867 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4819

PubMed: 30894630 ( click the link to review the publication )
Sci Rep, 2019, 9(1):7617

PubMed: 31110200 ( click the link to review the publication )

Sci Rep, 2019, 9(1):17171

PubMed: 31748572 ( click the link to review the publication )

Nanomaterials (Basel), 2019, 9(12)

PubMed: 31888247 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 369(3):531-545

PubMed: 30898866 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):485

PubMed: 31118072 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2019, 9:80-86

PubMed: 30771616 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2019, 84(6):1241-1256

PubMed: 31541266 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212210

PubMed: 30779812 ( click the link to review the publication )

PLoS One, 2019, 14(2):e0212860

PubMed: 30794695 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Environ Mol Mutagen, 2019, 60(6):513-533

PubMed: 30702769 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

J Immunol Methods, 2019, 464:22-30

PubMed: 30347189 ( click the link to review the publication )

Oncotarget, 2019, 10(31):2930-2946

PubMed: 31105876 ( click the link to review the publication )

Oncotarget, 2019, 10(23):2237-2251

PubMed: 31040916 ( click the link to review the publication )

J Extracell Vesicles, 2019, 9(1):1698889

PubMed: 31853340 ( click the link to review the publication )

Nat Neurosci, 2019, 22(5):719-728

PubMed: 30936558 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Sci Transl Med, 2018, 10(427)

PubMed: 29437150 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1523

PubMed: 29670076 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )
J Hematol Oncol, 2018, 11(1):85

PubMed: 29925404 ( click the link to review the publication )

Oncogene, 2018, 37(16):2104-2121

PubMed: 29379163 ( click the link to review the publication )

Oncogene, 2018, 37(21):2837-2849

PubMed: 29511345 ( click the link to review the publication )

Cell Mol Life Sci, 2018, 75(22):4223-4234

PubMed: 29955905 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Sci Signal, 2018, 11(539)

PubMed: 30018082 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):183

PubMed: 30081903 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):21

PubMed: 29776413 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1556-1567

PubMed: 29903769 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(7)

PubMed: 30036966 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5362

PubMed: 29599515 ( click the link to review the publication )

Food Chem Toxicol, 2018, 119:464-478

PubMed: 29097117 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Front Pharmacol, 2018, 9:403

PubMed: 29765318 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1285

PubMed: 30473665 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2061-2068

PubMed: 29620253 ( click the link to review the publication )

Cytokine, 2018, 111:209-215

PubMed: 30176559 ( click the link to review the publication )

Cell Adh Migr, 2018, 12(3):286-298

PubMed: 28678601 ( click the link to review the publication )

Toxicol Lett, 2018, 296:39-47

PubMed: 30086328 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

FEBS Open Bio, 2018, 8(5):732-742

PubMed: 29744288 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )
Oncotarget, 2018, 9(12):10723-10733

PubMed: 29535838 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Nature, 2018, 563(7730):265-269

PubMed: 30401838 ( click the link to review the publication )

Sci Transl Med, 2017, 9(374)

PubMed: 28123069 ( click the link to review the publication )

Sci Transl Med, 2017, 9(414)10

PubMed: 29093181 ( click the link to review the publication )

Blood, 2017, 129(11):e26-e37

PubMed: 28122742 ( click the link to review the publication )

Mol Cell, 2017, 66(5):635-647

PubMed: 28575659 ( click the link to review the publication )

Nat Commun, 2017, 8:14073

PubMed: 28102225 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(23):7360-7374

PubMed: 28939749 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):118

PubMed: 28606127 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2387-2398

PubMed: 28775147 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Neoplasia, 2017, 19(4):354-363

PubMed: 28319809 ( click the link to review the publication )

Toxicol Sci, 2017, 162(1):146-166

PubMed: 29106658 ( click the link to review the publication )

J Biol Chem, 2017, 292(35):14381-14390

PubMed: 28684419 ( click the link to review the publication )

Cancer Med, 2017, 6(4):809-818

PubMed: 28316141 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Clin Res Hepatol Gastroenterol, 2017, 41(6):677-686

PubMed: 28578938 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:73-83

PubMed: 28123301 ( click the link to review the publication )

J Neurophysiol, 2017, 118(1):595-609

PubMed: 28446585 ( click the link to review the publication )

Eur J Haematol, 2017, 99(5):442-448

PubMed: 28881484 ( click the link to review the publication )

Arch Pharm Res, 2017, 40(2):197-203

PubMed: 27988882 ( click the link to review the publication )
Mol Vis, 2017, 23:823-831

PubMed: 29225458 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Ther Drug Monit, 2017, 39(3):252-262

PubMed: 28490048 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3029

PubMed: 29048432 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(8):1903-1913

PubMed: 27931141 ( click the link to review the publication )

Hepatology, 2017, 66(6):1934-1951

PubMed: 28714104 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Blood Adv, 2017, 1(26):2610-2623

PubMed: 29296914 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(6):754-768

PubMed: 28618271 ( click the link to review the publication )

Oncotarget, 2017, 8(43):73871-73883

PubMed: 29088753 ( click the link to review the publication )

Nat Commun, 2016, 7:10060

PubMed: 26725982 ( click the link to review the publication )

Nat Commun, 2016, 7:11889

PubMed: 27297662 ( click the link to review the publication )

Nat Commun, 2016, 7:12428

PubMed: 27687249 ( click the link to review the publication )

Leukemia, 2016, 30(6):1273-81

PubMed: 26987906 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(51):E8228-E8237

PubMed: 27930322 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3520-30

PubMed: 27197167 ( click the link to review the publication )

Int J Cancer, 2016, 139(10):2359-69

PubMed: 27434411 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):80

PubMed: 27495374 ( click the link to review the publication )

Development, 2016, 143(10):1674-87

PubMed: 26989177 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(5):819-29

PubMed: 26883271 ( click the link to review the publication )
J Infect Dis, 2016, 213(11):1767-76

PubMed: 26802142 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Cancer, 2016, 16:229

PubMed: 26984511 ( click the link to review the publication )

PLoS One, 2016, 11(10):e0164895

PubMed: 27768734 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3598-3608

PubMed: 27900042 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

J Gen Virol, 2016, 97(5):1134-1144

PubMed: 26879209 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59236-59244

PubMed: 27494860 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Sci Transl Med, 2015, 7(284):284ra57

PubMed: 25904741 ( click the link to review the publication )

Blood, 2015, 125(8):1282-91

PubMed: 25515960 ( click the link to review the publication )

Leukemia, 2015, 29(3):586-597

PubMed: 25134459 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(1):262-8

PubMed: ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1275-86

PubMed: 25983018 ( click the link to review the publication )

J Cell Sci, 2015, 128(2):251-65

PubMed: ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.021

PubMed: ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

Clin Immunol, 2015, 157(2):205-215

PubMed: 25728491 ( click the link to review the publication )

Neurotox Res, 2015, 27(4):384-98

PubMed: 25782580 ( click the link to review the publication )

Arch Biochem Biophys, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25843419 ( click the link to review the publication )
PLoS One, 2015, 10(6):e0129663

PubMed: 26061184 ( click the link to review the publication )

Pulm Pharmacol Ther, 2015, 10.1016/j.pupt.2015.03.001

PubMed: 25843005 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):3249-3256

PubMed: 25975261 ( click the link to review the publication )

Int J Clin Exp Pathol, 2015, 8(7):7818-24

PubMed: 26339346 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(4):1967-80

PubMed: 25596742 ( click the link to review the publication )

Eur J Pharm Sci, 2015, 80:56-65

PubMed: 26296860 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015, 6(36):38854-65

PubMed: 26513174 ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12405-20

PubMed: 25915159 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Leukemia, 2014, 28(10):2109-12

PubMed: 24919804 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Cancer Lett, 2014, 344(1):90-100

PubMed: 24513268 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1023

PubMed: 24457967 ( click the link to review the publication )

Cell Death Dis, 2014, 6:e1595

PubMed: 25590805 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 14):3039-51

PubMed: 24928894 ( click the link to review the publication )

Int J Mol Sci, 2014, 15(4):5838-51

PubMed: 24714091 ( click the link to review the publication )
Exp Cell Res, 2014, 328(1):20-31

PubMed: 25128812 ( click the link to review the publication )

J Pharm Biomed Anal, 2014, 94:125-31

PubMed: 24561338 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107367

PubMed: 25198091 ( click the link to review the publication )

PLoS One, 2014, 9(1):e85485

PubMed: 24427313 ( click the link to review the publication )

Mol Biosyst, 2014, 10.1039/C4MB00224E

PubMed: 25099472 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Leuk Lymphoma, 2014, 10.3109/10428194.2014.898759

PubMed: 24597981 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Head Neck, 2014, 36(3):375-84

PubMed: 23729178 ( click the link to review the publication )

Graefes Arch Clin Exp Ophthalmol, 2014, 10.1007/s00417-014-2674-7

PubMed: 24874745 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Exp Med, 2013, 210(11):2205-21

PubMed: 24127489 ( click the link to review the publication )

J Exp Med, 2013, 210(12):2569-82

PubMed: 24190431 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5053-67

PubMed: 23900136 ( click the link to review the publication )

PLoS Biol, 2013, 11(3):e1001515

PubMed: 23526884 ( click the link to review the publication )

Cancer Lett, 2013, 340(1):43-50

PubMed: 23811285 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Neoplasia, 2013, 15(11):1272-81

PubMed: 24339739 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2013, 145(2):531-8

PubMed: 23142123 ( click the link to review the publication )

J Neurochem, 2013, 12(12):2864-73

PubMed: 24130049 ( click the link to review the publication )

J Biol Chem, 2013, 288(8):5553-61

PubMed: 23303179 ( click the link to review the publication )

Int J Oncol, 2013, 43(6):2064-72

PubMed: 24126464 ( click the link to review the publication )
Cancer Chemother Pharmacol, 2013, 72(1):35-44

PubMed: 23712327 ( click the link to review the publication )

Pharmgenomics Pers Med, 2013, 6:63-72

PubMed: 24019750 ( click the link to review the publication )

Sci Rep, 2013, 3:2100

PubMed: 23812503 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2978-91

PubMed: 23974111 ( click the link to review the publication )

Sci Transl Med, 2012, 4(136):136ra70

PubMed: 22649091 ( click the link to review the publication )

Blood, 2012, 119(21):4981-91

PubMed: 22411867 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(1):127-39

PubMed: 22090359 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(17):6584-10

PubMed: 22492965 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Br J Haematol, 2012, 157(4):510-4

PubMed: 22313359 ( click the link to review the publication )

J Virol, 2012, 86(16):8765-72

PubMed: 22696643 ( click the link to review the publication )

Angiogenesis, 2012, 15(1):33-45

PubMed: 22203239 ( click the link to review the publication )

Cancer Immunol Immun, 2012, 61(2):193-202

PubMed: 21874302 ( click the link to review the publication )

Invest New Drugs, 2012, 30(1):417-22

PubMed: 20953816 ( click the link to review the publication )

Stem Cells Dev, 2012, 21(16):2939-48

PubMed: 22642671 ( click the link to review the publication )

Hematol Oncol, 2012, 31(3):156-63

PubMed: 23108877 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40853

PubMed: 22815843 ( click the link to review the publication )

J Biomol Screen, 2012, 18(4):388-99

PubMed: 23134735 ( click the link to review the publication )

J Liq Chromatogr R T, 2012, 2503-2510

PubMed: ( click the link to review the publication )

Cell Res, 2011, 21(7):1080-7

PubMed: 21423276 ( click the link to review the publication )

J Mol Biol, 2011, 411(2):474-85

PubMed: 21699901 ( click the link to review the publication )

J Virol, 2011, 85(5):2296-303

PubMed: 21177802 ( click the link to review the publication )

Cancer Prev Res , 2011, 4(8):1222-32

PubMed: 21546539 ( click the link to review the publication )

J Biol Chem, 2011, 286(16):13846-51

PubMed: 21343293 ( click the link to review the publication )
Exp Hematol, 2011, 39(8):859-65.e2

PubMed: 21689725 ( click the link to review the publication )

PLoS One, 2010, 5(11):e14143

PubMed: 21152443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	Src ^[1] (Cell-free assay)	c-Kit (D816V) ^[2] (Cell-free assay)	c-Kit (wt) ^[2] (Cell-free assay)
0.6 nM	0.8 nM	37 nM	79 nM

In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. ^[1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. ^[3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
M07ep210	NY\Hc3VJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXm3NkBp	NFzXe5lFVVOR	MYDJR\|UxRTBwMECwNFch\|ryP	MnvLNVc6PTZyOEC=
K562	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{\xfFczKGh?	M4LPUWROW09?	NEDIdmtKSzVyPUCuNFAyKM7:TR?=	MlvsNVc6PTZyOEC=
M07e	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MorvO\|IhcA>?	NIHs[pVFVVOR	M17vcGlEPTB;MD6wNFEzKM7:TR?=	NWXqSYZlOTd7NU[wPFA>
ALL3	Mk\jR5l1d3SxeHnjJGF{e2G7	M3HW[\|AvOc7:TR?=	MoC4O\|IhcA>?	MYDEUXNQ	NFvKc4dKSzVyPUCuNFAxPCEQvF2=	NWjPZmluOTl6OEm1OFA>
CML	NILRfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWSyNEBucW5?	MYDEUXNQ	NUni[48zUUN3ME2wMlAxOSEQvF2=	MXKxPVIyQTBzNh?=
BA/F3	MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1fqfVczKGh?	MV3EUXNQ	NUTVNmkzUUN3ME22MlU5QSEQvF2=	M3W5blI{ODh6NkS0
BA/F3	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH6zOpQ4OiCq	NV\mZ2dMTE2VTx?=	NFvleXBKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW\|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=>	NF6yeHAzOzB6OE[0OC=>
BA/F3	MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M16xeVczKGh?	M{jLe2ROW09?	MnPMTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>?	NFHHWpEzOzB6OE[0OC=>
BA/F3	M1PhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYL4XVFNPzJiaB?=	MVfEUXNQ	M2Xwfmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO\|aX7nJGJkei2DYnygWFMyPUlibYX0ZY51KHerdHigTWM2OCCxZjCxMlcyPM7:TR?=	MlfzNlMxQDh4NES=
BA/F3	NF\TdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGjE[Jk4OiCq	NFywOFRFVVOR	NGOy[nRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFAxQc7:TR?=	NVHoVXpUOjN\|MEG3NFM>
BA/F3	NWrZc49uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUjnZlVvPzJiaB?=	NUewZYk6TE2VTx?=	MXHJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>?	MYiyN\|MxOTdyMx?=
BA/F3	NUfI[\|JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHHlPYs4OiCq	NWfyflRoTE2VTx?=	NH;wbJpKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFA2Oc7:TR?=	MlvkNlM{ODF5MEO=
BA/F3	NV3HOZp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnzwO\|IhcA>?	MX;EUXNQ	MnjmTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>?	Mn;PNlM{ODF5MEO=
BA/F3	MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXT4TWdFPzJiaB?=	MX3EUXNQ	M{nIdmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV\|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{\|ryP	NIP1RpkzOzNyMUewNy=>
BA/F3	M13tfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUS3NkBp	MUnEUXNQ	MWXJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO\|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=>	NULJSplvOjN\|MEG3NFM>
BA/F3	MlXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWK3NkBp	NE\QUItFVVOR	NFfnclRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO\|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR\|UxKG:oIECuNFAzO87:TR?=	MoXONlM{ODF5MEO=
BA/F3	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLaWJI4OiCq	NXnCPYRLTE2VTx?=	MYXJcoR2[2W\|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=>	Mn7TNlM{ODF5MEO=
BA/F3	NV3qTZdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY[3NkBp	NGDtcVNFVVOR	NHXidVRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2=	MYCyN\|MxOTdyMx?=
T cell	NEC5fIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnLlO\|IhcA>?	Ml[ySG1UVw>?	NWfWXlNSUW6qaXLpeJMh[W62aTDDSFMuKGGwZDDhcpRqKEOGMkitbY5lfWOnZDDUJINmdGxicILvcIln\XKjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFPPxE1?	MlfvNVcyPTR3MUK=
WiDr	NFLKRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M13JcVczKGh?	M3;1[2ROW09?	NUHySVV7UUN3ME2wMlA2OiEQvF2=	MlznNVU3OTV3MUK=
PC3	M1LLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnXIO\|IhcA>?	NF3hcGhFVVOR	NULw[oMxUUN3ME2wMlAxQTRizszN	NUnLc4hCOTV4MUW1NVI>
MDA-MB-231	M4LJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX23NkBp	Mk\ESG1UVw>?	NH;xdXhKSzVyPUCuNFEzKM7:TR?=	MlPxNVU3OTV3MUK=
Hs578T	NGfkSG1EgXSxdH;4bYMhSXO\|YYm=		NFr0ZnM4OiCq	NWDaOXlZTE2VTx?=	MYHHTVUxRTBwMEOg{txO	MVGyOFAyPTN{Nx?=
HMEC	MX;DfZRwfG:6aXOgRZN{[Xl?		MVK3NkBp	MYXEUXNQ	MojrS2k2OD1zLkig{txO	M1GzN\|I1ODF3M{K3
DU145	NEfpVYFEgXSxdH;4bYMhSXO\|YYm=		NV72SlU4PzJiaB?=	MnvKSG1UVw>?	MmfOS2k2OD1yLkG2JO69VQ>?	MmXJNlQxOTV\|Mke=
U251	NUC1VZRbS3m2b4TvfIlkKEG\|c3H5		M3rze\|czKGh?	MXTEUXNQ	M4qzOWdKPTB;Mj64NUDPxE1?	NX:w[ZFqOjRyMUWzNlc>
NCI60	MUXDfZRwfG:6aXOgRZN{[Xl?		MXK3NkBp	NXvzUJlGTE2VTx?=	M376UGdKPTB;NT63JO69VQ>?	M2\1TlI1ODF3M{K3
MALME-3M	NV3o[pVmS3m2b4TvfIlkKEG\|c3H5		NXHGV4diPzJiaB?=	NHftXZZFVVOR	MXzHTVUxRTZwNkGg{txO	MVqyOFAyPTN{Nx?=
KM12	MoL0R5l1d3SxeHnjJGF{e2G7		NX\ZUYluPzJiaB?=	NV\Vd5BQTE2VTx?=	NWrNS5luT0l3ME23MlQ1KM7:TR?=	MVGyOFAyPTN{Nx?=
SW620	NVfJXZdOS3m2b4TvfIlkKEG\|c3H5		NFXYdlY4OiCq	NHfUVpdFVVOR	MXjHTVUxRThwNEOg{txO	NXPaemo4OjRyMUWzNlc>
RXF 393NL	MnLpR5l1d3SxeHnjJGF{e2G7		NUjj[JprPCCmYYnz	NGf5b3RFVVOR	NXvMNHFXUUN3ME2wMlAzOTdizszN	NHmwfYgzOzJ3M{C3OC=>
LXFA 983L	Mn;vR5l1d3SxeHnjJGF{e2G7		MUW0JIRigXN?	MofISG1UVw>?	MUjJR\|UxRTBwMEW2OUDPxE1?	M{fYO\|I{OjV\|MEe0
PRXF DU145	MWXDfZRwfG:6aXOgRZN{[Xl?		MknOOEBl[Xm\|	NX31PGtKTE2VTx?=	MV\JR\|UxRTBwME[yN{DPxE1?	NVO1d3JKOjN{NUOwO\|Q>
PAXF 1657L	MoryR5l1d3SxeHnjJGF{e2G7		M1j5clQh\GG7cx?=	MnLjSG1UVw>?	MV;JR\|UxRTBwMUKxJO69VQ>?	NIrndpMzOzJ3M{C3OC=>
CXF 1103L	M2DFSWN6fG:2b4jpZ{BCe3OjeR?=		M{Dkc\|Qh\GG7cx?=	NX63WYVLTE2VTx?=	NUXUfFlOUUN3ME20MlM3KM7:TR?=	MYiyN\|I2OzB5NB?=
GXF251L	NIrvdVdEgXSxdH;4bYMhSXO\|YYm=		NUflXI9uPCCmYYnz	M4TqXWROW09?	MnfSTWM2OD1{LkK1JO69VQ>?	NXnXNnNTOjN{NUOwO\|Q>
NCI-H23	NGLudoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn3sO\|IhcA>?	NXjKXFJoTE2VTx?=	M1;GUWlEPTB;Mj6yO{DPxE1?	M{\zVFI{PTJzMEKw
HCT116	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkfMO\|IhcA>?	MXLEUXNQ	M4HaTmlEPTB;Mj6zJO69VQ>?	NVHSUnJjOjN3MkGwNlA>
MCF7	NEnZbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnrTO\|IhcA>?	NGO2TYVFVVOR	MY\JR\|UxRTJwNUeg{txO	NVXCRWxkOjN3MkGwNlA>
NCI-H460	NXzWNHNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVz2Z3dKPzJiaB?=	NIfMSnJFVVOR	NG\xNFZKSzVyPUiuPVkh\|ryP	MWCyN\|UzOTB{MB?=
DLD1	MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmXrO\|IhcA>?	NYnxWo1JTE2VTx?=	NV6wNGt5UUN3ME20MlYh\|ryP	M2nHUVI{PTZ5OU[w
NCI-H661	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYjib\|I4PzJiaB?=	NHPYdZlFVVOR	NFnQXJNKSzVyPUeuPEDPxE1?	Mmi1NlM2Pjd7NkC=
A549	NYDITYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYW3NkBp	NES3R2pFVVOR	NXHa[o02UUN3ME24MlIh\|ryP	MVmyN\|U3Pzl4MB?=
U937	NYTyfWxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NILWcnY4OiCq	Ml3zSG1UVw>?	NFXDWW9KSzVyPUGyMlIh\|ryP	M4HhUVI{PTZ5OU[w
HEK293	M33ZXGZ2dmO2aX;uJGF{e2G7	NYXrc2VTOTEEoN88US=>		NHLPXZFFVVOR	MV;JcoR2[2W\|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?=	MoSxNlI4PzB4MUC=
HUVEC	NE\MWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7vW\|g6OC5zNdMg{txO	M2TVXlczKGh?	MonRSG1UVw>?	MXrJcoR2[2W\|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG\|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2=	M3f0bVIzQDV\|OUmz
HUVEC	MkXuSpVv[3Srb36gRZN{[Xl?	MVyxOeKh\|ryP	M3n5TFczKGh?	MlnrSG1UVw>?	NFzLco5KdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>?	M4TpSFIzQDV\|OUmz
Plasmodium falciparum	MWrGeY5kfGmxbjDBd5NigQ>?	NFfSdogyOMLizszN	Mnz1NVUhdWmw	M2rOZmROW09?	NFz2NHJKdmirYnn0d{BRdGG\|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR\|UxKG:oIEGuNVfPxE1?	MXuyOFU2ODN\|MB?=
PC3	Ml\oSpVv[3Srb36gRZN{[Xl?	NVPQOmhnOC5zIN88US=>	NVj6e\|V4PSCq	M1XqUGROW09?	M{T1dGlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?=	M4f1clE6PDZ{OUe1
DU145	M3X3[2Z2dmO2aX;uJGF{e2G7	Mly0NE4yKM7:TR?=	MXy1JIg>	M4q2eWROW09?	M1jwTmlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N	NXLaZnpvOTl2NkK5O\|U>
PC3	MoL4T4lv[XOnIFHzd4F6	NWXIcI5KOC5zIN88US=>	NF74[mo2KGh?	Mle0SG1UVw>?	M2TkUWlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2=	Mo\NNVk1PjJ7N{W=
DU145	NXT3O402U2mwYYPlJGF{e2G7	NFzLdmkxNjFizszN	MVG1JIg>	M3LSW2ROW09?	M121WWlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=>	NGHkSZIyQTR4Mkm3OS=>
PC3	NFTtOY5McW6jc3WgRZN{[Xl?	NFnsV\|cxNjFizszN	MnzWOUBp	MmHBSG1UVw>?	M2HCSmlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBHSUtiWUW3Ok9[PTd5IHzleoVtKGG2IEGwNEBvVQ>?	NHn2V2IyQTR4Mkm3OS=>
DU145	NF:3d2ZMcW6jc3WgRZN{[Xl?	NFO2cXUxNjFizszN	M1nG[\|UhcA>?	MX3EUXNQ	M2\QeGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P	NIHlOYIyQTR4Mkm3OS=>
Huh7	M4q2WGFvfGm4aYLhcEBCe3OjeR?=	NYjpZ5RUOi53IN88US=>	MlzzOEBl[Xm\|	M1u1WmROW09?	NYX0PYd5UW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN	MWKxO\|M3ODZ5Nh?=
C6/36	NGnybVVCdnSrdnnyZYwhSXO\|YYm=	M1HZWVIvPSEQvF2=	NIXUU3c1KGSjeYO=	Mn;XSG1UVw>?	Mk\lTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>?	M4\kZlE4OzZyNke2
U937	MW\GeY5kfGmxbjDBd5NigQ>?	MYKxJO69VQ>?	NEnYdnUyKGh?	M4DYUWROW09?	M3O2b3Jm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy\|	M4fZOFE4Pjh2MEm5
U937	NHnNRWdHfW6ldHnvckBCe3OjeR?=	NX2xbHdVOSEQvF2=	NU\FPGk5OSCq	NY\OcIZUTE2VTx?=	M{fYbnJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{	NXryVW5QOTd4OESwPVk>
murine mast cell	M2XUdmZ2dmO2aX;uJGF{e2G7	NF\zRZQyKM7:TR?=	Mn;vNlQhcA>?	MYXEUXNQ	MmrvTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy\|IHH0JFEhfU1?	M1LxOFE4Pjh2MEm5
BV-173	M4TaNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfl[ndwUUN3ME2wMlAxODByMEGwPUDPxE1?	MoHsV2FPT0WU
K-562	NUfNeYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7zTWM2OD1yLkCwNFAxODJ4NjFOwG0>	MU\TRW5ITVJ?
BL-70	M{L0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV20W4tZUUN3ME2wMlAxODByMEiyNkDPxE1?	NX23[ItIW0GQR1XS
EM-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjFfJBKSzVyPUCuNFAxODBzMEig{txO	NV3CN4J3W0GQR1XS
LAMA-84	M2DQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDmdVJKSzVyPUCuNFAxODB\|MkGg{txO	MYTTRW5ITVJ?
MEG-01	M2DMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vnO2lEPTB;MD6wNFAxODl6IN88US=>	NVqxVnlkW0GQR1XS
EoL-1-cell	NULUNoJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlO1TWM2OD1yLkCwNFAyOzFizszN	M{XtXnNCVkeHUh?=
CTV-1	NVzEUFBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXruUnJ7UUN3ME2wMlAxODB2MESg{txO	MmW1V2FPT0WU
TE-15	NH:yfppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjZTWM2OD1yLkCwOVg6KM7:TR?=	M3XD[XNCVkeHUh?=
NOS-1	M{nPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2Lm[GlEPTB;MD6wNFYyOyEQvF2=	NXLxU49WW0GQR1XS
D-336MG	M1jkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTaTWM2OD1yLkCwOlMh\|ryP	Ml;lV2FPT0WU
LB1047-RCC	NGLWUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7nNXlJUUN3ME2wMlAxQTh7IN88US=>	NWn0RmRRW0GQR1XS
LB996-RCC	M4nUZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWniSJkzUUN3ME2wMlAxQTlzIN88US=>	MVXTRW5ITVJ?
SW982	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTBwMEGxNVUh\|ryP	Mn;EV2FPT0WU
TK10	NUm4R2lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3LflhKSzVyPUCuNFEyPzRizszN	NYO1O3pEW0GQR1XS
A704	M2XyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPON4NKSzVyPUCuNFE1QTFizszN	NWC2V\|AzW0GQR1XS
TE-8	Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUO4XGhxUUN3ME2wMlAyPTd4IN88US=>	NEPJfYtUSU6JRWK=
DOHH-2	M{HJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDMZWZKSzVyPUCuNFE4OTlizszN	MUDTRW5ITVJ?
HOP-62	M2DHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkj6TWM2OD1yLkCxPFM1KM7:TR?=	NFPpfoxUSU6JRWK=
TE-12	NHW2fW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfWfXhKSzVyPUCuNFE5PjFizszN	NIi0bHFUSU6JRWK=
KGN	MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPYWZhZUUN3ME2wMlAyQTR{IN88US=>	MmrSV2FPT0WU
NCI-H1648	MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVm1T3U5UUN3ME2wMlAzODFzIN88US=>	NV7QT5ozW0GQR1XS
OS-RC-2	NFvubFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFr2cmtKSzVyPUCuNFIxOyEQvF2=	NEK5WXpUSU6JRWK=
GB-1	M4r2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnH6TWM2OD1yLkCyNVU4KM7:TR?=	MXTTRW5ITVJ?
RXF393	NHLncohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nsWGlEPTB;MD6wNlM2PyEQvF2=	NEe0SGtUSU6JRWK=
LC-2-ad	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjv[HJlUUN3ME2wMlAzPTh4IN88US=>	M3XVNXNCVkeHUh?=
KS-1	NULNfHlXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37JNGlEPTB;MD6wNlc{KM7:TR?=	MmTYV2FPT0WU
ETK-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PEfGlEPTB;MD6wNlg{OiEQvF2=	MVfTRW5ITVJ?
SW954	NHSwfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTBwMEK5Nlch\|ryP	MYHTRW5ITVJ?
Becker	M1fUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYS4c2ZUUUN3ME2wMlA{ODB\|IN88US=>	NXzvWmxPW0GQR1XS
MZ1-PC	M{C2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zDNmlEPTB;MD6wN\|EyQSEQvF2=	M4f3dnNCVkeHUh?=
ES6	NWr2e4tOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfXTWM2OD1yLkCzNVk{KM7:TR?=	MUXTRW5ITVJ?
KURAMOCHI	M1LWOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\HNo5KSzVyPUCuNFM1QDdizszN	MYDTRW5ITVJ?
CGTH-W-1	NWfB[ot2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTBwMEO1OFgh\|ryP	MX7TRW5ITVJ?
VA-ES-BJ	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofiTWM2OD1yLkCzPVAzKM7:TR?=	M{C4RnNCVkeHUh?=
LXF-289	NXvxR2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmK2TWM2OD1yLkCzPVU3KM7:TR?=	MoTMV2FPT0WU
MPP-89	M1\ZTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLNTWM2OD1yLkC0NFQ6KM7:TR?=	M{T0[nNCVkeHUh?=
SW872	M2HJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknBTWM2OD1yLkC0NVYyKM7:TR?=	MYfTRW5ITVJ?
SNB75	NYHaSZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTBwMES0N\|Uh\|ryP	NXm4dlhJW0GQR1XS
PSN1	MnHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEG2PYlKSzVyPUCuNFQ1PzRizszN	MUXTRW5ITVJ?
LB831-BLC	M3\4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DXcWlEPTB;MD6wOFYxQSEQvF2=	NFPGNHlUSU6JRWK=
MFH-ino	MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7KO3NSUUN3ME2wMlA1PzJ2IN88US=>	NHrCb4NUSU6JRWK=
TGBC24TKB	NXjFNmRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPsZ4xJUUN3ME2wMlA1PzZzIN88US=>	NIrQU\|RUSU6JRWK=
A388	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXHbmRKSzVyPUCuNFUxQTVizszN	MVnTRW5ITVJ?
BB30-HNC	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrRZXhKSzVyPUCuNFU1OzdizszN	M2H0UnNCVkeHUh?=
GI-ME-N	NUOwSWlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXLTWM2OD1yLkC2NVE5KM7:TR?=	MmjMV2FPT0WU
TGBC1TKB	MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkDETWM2OD1yLkC2NVY1KM7:TR?=	NGLVO2dUSU6JRWK=
TE-10	NUDEdoVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPodm9KSzVyPUCuNFY{PTdizszN	M3iye3NCVkeHUh?=
A498	NVvsfG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\jSHVKSzVyPUCuNFczQDRizszN	MmjXV2FPT0WU
TE-11	M3q1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUL3UnhkUUN3ME2wMlA4QDV6IN88US=>	MkixV2FPT0WU
BB65-RCC	NX3XOXpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXHJR\|UxRTBwMEiyNlch\|ryP	M33vTnNCVkeHUh?=
C2BBe1	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2O0cWlEPTB;MD6wPFMxQCEQvF2=	M1TT[3NCVkeHUh?=
NCI-H747	NX[1WpBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvRTWM2OD1yLkC4N\|YzKM7:TR?=	M{L2S3NCVkeHUh?=
IST-MES1	M4Pze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTBwMEi1OVIh\|ryP	M1jwZXNCVkeHUh?=
KALS-1	MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLHTWM2OD1yLkC5OFkh\|ryP	Ml\iV2FPT0WU
GCIY	NHfud2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvhTWM2OD1yLkC5OlU3KM7:TR?=	M37tcHNCVkeHUh?=
RL95-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NET1WppKSzVyPUCuNVA{QCEQvF2=	NXK0N5BNW0GQR1XS
TE-1	NX\6[ZI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETJUWRKSzVyPUCuNVA2PCEQvF2=	NWTiSmxoW0GQR1XS
NCI-H1355	M1z3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTPbZdVUUN3ME2wMlEyODJ6IN88US=>	MW\TRW5ITVJ?
SW962	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTBwMUGyPVIh\|ryP	MlvZV2FPT0WU
KLE	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTjcnpwUUN3ME2wMlEyOzF5IN88US=>	NEHwXI1USU6JRWK=
MC116	NHftN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{D0UmlEPTB;MD6xNVQyKM7:TR?=	M{WwTnNCVkeHUh?=
NMC-G1	NXXxWIxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2XXPWlEPTB;MD6xNVYxPiEQvF2=	MWnTRW5ITVJ?
KU812	NXPaUIgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTMTWM2OD1yLkGxPFg{KM7:TR?=	NIHoR25USU6JRWK=
COLO-829	NILqOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjz[FRKSzVyPUCuNVIzOTNizszN	MXHTRW5ITVJ?
NTERA-S-cl-D1	M3jLb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTBwMUKyPFMh\|ryP	NYmyfZNvW0GQR1XS
IST-MEL1	NWH1XYR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTBwMUO0OUDPxE1?	MVTTRW5ITVJ?
MLMA	NHTkPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTOeW5zUUN3ME2wMlE1ODN{IN88US=>	NE\tWGpUSU6JRWK=
LS-123	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlizTWM2OD1yLkG0NFY1KM7:TR?=	NX;zdFZpW0GQR1XS
LB2518-MEL	NEmxcJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1viRmlEPTB;MD6xOFE3OiEQvF2=	M1;sVHNCVkeHUh?=
NB69	MnO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\ZUGVRUUN3ME2wMlE1PDN4IN88US=>	Mn;OV2FPT0WU
8-MG-BA	NVexTIZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnNW3VUUUN3ME2wMlE2PDV6IN88US=>	NWfZcJhqW0GQR1XS
K5	NU\IXJZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;JS\|ZKSzVyPUCuNVY1QDlizszN	NGjrbnNUSU6JRWK=
KINGS-1	M1ex[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfsUpp4UUN3ME2wMlE3PjZ4IN88US=>	MlK4V2FPT0WU
SF268	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fJTWlEPTB;MD6xO\|QxPCEQvF2=	M{PlWXNCVkeHUh?=
PF-382	NIr2eVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{KyOWlEPTB;MD6xO\|Y4QCEQvF2=	MlvSV2FPT0WU
SH-4	M3XDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHibmhQUUN3ME2wMlE5PDF\|IN88US=>	MYDTRW5ITVJ?
NALM-6	MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTBwMUmyPVUh\|ryP	MnjnV2FPT0WU
CP66-MEL	MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLZTWM2OD1yLkG5OVMyKM7:TR?=	NF76ZWJUSU6JRWK=
697	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvXTWM2OD1yLkG5PVg4KM7:TR?=	MoLUV2FPT0WU
CP67-MEL	NYTwbIhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHL5NolKSzVyPUCuNlA1QDhizszN	MV;TRW5ITVJ?
DSH1	NFHDcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjtUIdKSzVyPUCuNlQxODFizszN	NUC2WmREW0GQR1XS
HCE-4	MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17HRmlEPTB;MD6yOlQ{QSEQvF2=	NHn5Vm5USU6JRWK=
MZ2-MEL	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\o[HV5UUN3ME2wMlI5PTN5IN88US=>	NIHsd49USU6JRWK=
BL-41	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPZN2tKSzVyPUCuNlkyOjNizszN	M1fHNXNCVkeHUh?=
HUTU-80	Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PEc2lEPTB;MD6zNVQzKM7:TR?=	NUPw[nNxW0GQR1XS
LOXIMVI	NXi4UJdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fWe2lEPTB;MD6zNVUxOyEQvF2=	MUnTRW5ITVJ?
no-10	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnTcXVmUUN3ME2wMlMyQTNzIN88US=>	MVTTRW5ITVJ?
KARPAS-422	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFr1U4tKSzVyPUCuN\|M6QTdizszN	Mnr6V2FPT0WU
SW684	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXNTWM2OD1yLkO0PVgh\|ryP	NVnTeVM4W0GQR1XS
SF126	M3fCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXH5PHpxUUN3ME2wMlM2PDFizszN	NUnsUIlMW0GQR1XS
D-263MG	NX3rfXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfTNFRPUUN3ME2wMlM3OjJ2IN88US=>	MnHXV2FPT0WU
OVCAR-4	NIPiZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrSNXlOUUN3ME2wMlM4PDN\|IN88US=>	MXvTRW5ITVJ?
BB49-HNC	NHn3bnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LIS2lEPTB;MD6zPFU6QSEQvF2=	MlqwV2FPT0WU
ONS-76	M3XyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HTNWlEPTB;MD60Nlk2OSEQvF2=	MljBV2FPT0WU
MZ7-mel	M3;y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjRZ41KSzVyPUCuOFc6OTFizszN	NGW3cGFUSU6JRWK=
RCC10RGB	NVv3NIVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjZWW54UUN3ME2wMlQ6OTFizszN	MYnTRW5ITVJ?
BOKU	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTBwNEmxN\|Mh\|ryP	MmnJV2FPT0WU
no-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrSe41KSzVyPUCuOVAzOjhizszN	Mn2wV2FPT0WU
IST-SL2	MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFja[XJKSzVyPUCuOVA{ODJizszN	M4LBOHNCVkeHUh?=
RKO	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXXbYxKSzVyPUCuOVI6PjZizszN	NIPLOGRUSU6JRWK=
HT-144	NIXrXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\aT5RZUUN3ME2wMlU{PjB7IN88US=>	MV;TRW5ITVJ?
NCI-H446	MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\R[3VkUUN3ME2wMlYzPzZizszN	MWLTRW5ITVJ?
QIMR-WIL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\1XHNnUUN3ME2wMlcxPjJ7IN88US=>	MmjJV2FPT0WU
MHH-PREB-1	MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfnfpdKSzVyPUCuO\|Q1PjlizszN	MYXTRW5ITVJ?
EW-16	NGnm[WtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DVO2lEPTB;MD63OlE4QCEQvF2=	NF7NUlFUSU6JRWK=
EW-24	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTBwN{ixOlUh\|ryP	NYTL[XNLW0GQR1XS
LB373-MEL-D	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTBwOEK1NFgh\|ryP	MWXTRW5ITVJ?
TE-9	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWPJR\|UxRTBwOEe1N\|Ih\|ryP	NUKwZWs1W0GQR1XS
A3-KAW	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTBwOUi0OVIh\|ryP	Mlj0V2FPT0WU
A101D	NH\CcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NY\hRWpiUUN3ME2xMlA{ODR\|IN88US=>	MlvjV2FPT0WU
OCUB-M	M1XoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\yc295UUN3ME2xMlA1PDF{IN88US=>	NHW3U3FUSU6JRWK=
ES4	NVr1NII{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFwMEWxOFUh\|ryP	NH3yN2hUSU6JRWK=
TE-6	MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTFwMkGyNlYh\|ryP	NET0SHZUSU6JRWK=
D-502MG	NFu0TXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1z2UmlEPTB;MT6yN\|M4PiEQvF2=	MoXJV2FPT0WU
KNS-42	M2rr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTFwMkS0NVIh\|ryP	NUDa[mtXW0GQR1XS
SNU-C2B	NG\3ZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mlm3TWM2OD1zLkOwOVg6KM7:TR?=	Mm\GV2FPT0WU
NCI-H1838	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLUTYxoUUN3ME2xMlMxPzN\|IN88US=>	NH;CS3NUSU6JRWK=
NKM-1	NH7Tc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rINGlEPTB;MT6zNFg2QSEQvF2=	M3PvTXNCVkeHUh?=
GI-1	NW[2bYM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4LvS2lEPTB;MT6zOlIzKM7:TR?=	NE\F[XFUSU6JRWK=
NB5	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7nTWM2OD1zLkO5PFI4KM7:TR?=	MWjTRW5ITVJ?
CAS-1	MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTFwNEC5PVIh\|ryP	MkLkV2FPT0WU
HCE-T	M1LrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLDW4NKSzVyPUGuOVY4OTRizszN	NF74fmpUSU6JRWK=
SBC-1	M2[0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHFeWNKSzVyPUGuOVc6QDRizszN	M1rpU3NCVkeHUh?=
JiyoyeP-2003	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFwN{O0OlYh\|ryP	NIjLXIFUSU6JRWK=
TE-5	NF\PeVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDEU\|JXUUN3ME2xMlc6OTN7IN88US=>	NVXlV4pzW0GQR1XS
CAN	NUjBTlA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TuVmlEPTB;MT64NlI2OiEQvF2=	NVnSXHhQW0GQR1XS
SK-UT-1	MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1TXeWlEPTB;Mj6xOlY6OyEQvF2=	NIqzXXZUSU6JRWK=
JVM-2	NX6wbY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vGTGlEPTB;Mj6zOlI5PCEQvF2=	MUTTRW5ITVJ?
LB771-HNC	M1f5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\nO5RKSzVyPUKuOVc2PTFizszN	Ml\RV2FPT0WU
NCCIT	NWHtWo9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjaeFVKSzVyPUKuPFY3OTZizszN	M1\GNnNCVkeHUh?=
NCI-H2126	Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkW2TWM2OD1{Lki3OVUzKM7:TR?=	NGLrOmpUSU6JRWK=
Calu-6	NVPGR3JJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnX2TWM2OD1\|LkC1O\|QyKM7:TR?=	NFjRb\|JUSU6JRWK=
SK-LMS-1	M{fWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTNwMUG4PFYh\|ryP	M1G1W3NCVkeHUh?=
ARH-77	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTBTWM2OD1\|LkS2PVE2KM7:TR?=	MoXSV2FPT0WU
NB17	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTsfnVTUUN3ME2zMlY{QDR5IN88US=>	MX;TRW5ITVJ?
A253	NELuZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1Pse2lEPTB;Mz63N\|I1PiEQvF2=	NF3ONZBUSU6JRWK=
OPM-2	M2Hvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvqTWM2OD12LkK3Olg2KM7:TR?=	MX;TRW5ITVJ?
MV-4-11	NYfR[XdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nPVWlEPTB;ND6zOlQ2PCEQvF2=	NUH3fXI4W0GQR1XS
SR	MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF32c4tKSzVyPUSuOFk6PTRizszN	M2XHTnNCVkeHUh?=
KG-1	NEXEXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTRwNkC4OFUh\|ryP	M2KybnNCVkeHUh?=
OCI-AML2	M2j1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojETWM2OD13Lki2NVU1KM7:TR?=	M2PCbXNCVkeHUh?=
D-247MG	NXGwN291T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHr6TY9KSzVyPU[uNVI2OTlizszN	M2LLTnNCVkeHUh?=
DJM-1	M{Dnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PDU2lEPTB;Nj60PFU2QCEQvF2=	NUXKZ5o2W0GQR1XS
RPMI-6666	M2C4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnCU2tzUUN3ME23MlI4ODZ5IN88US=>	MVvTRW5ITVJ?
KARPAS-45	M3H1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4D2eGlEPTB;Nz61NVY4OSEQvF2=	M13oUnNCVkeHUh?=
LP-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTdwNUS3PFIh\|ryP	M2T6VHNCVkeHUh?=
RS4-11	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTdwNkW3PFch\|ryP	Ml;TV2FPT0WU
DU-4475	NG\nVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;aNINKSzVyPUiuNlE3PTJizszN	M1XofXNCVkeHUh?=
MONO-MAC-6	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDxdlg4UUN3ME24MlI4ODZ4IN88US=>	MVnTRW5ITVJ?
NCI-SNU-16	M2fmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTJN3VkUUN3ME24MlU3OTJ6IN88US=>	M4DjbXNCVkeHUh?=
SJSA-1	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHn1VHNKSzVyPUiuO\|I5ODVizszN	NYfRclJvW0GQR1XS
MMAC-SF	NIPIcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvveZpKSzVyPUiuO\|k{ODdizszN	Mk[5V2FPT0WU
SK-NEP-1	M3;W[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETw[G5KSzVyPUiuPFkyPTVizszN	M{ezVXNCVkeHUh?=
J-RT3-T3-5	NFnPTo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHnTXR[UUN3ME24Mlk3PTJ7IN88US=>	NXzae\|B{W0GQR1XS
SKM-1	NV3PWIJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTlwMEG3N\|Qh\|ryP	MVPTRW5ITVJ?
LB2241-RCC	NEiwSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2m3S2lEPTB;OT6wNlAyOiEQvF2=	NIHhelJUSU6JRWK=
SIG-M5	M1Xo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfVPZZwUUN3ME25MlAzPDl\|IN88US=>	NYrtcphYW0GQR1XS
EVSA-T	NGrXWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTlwMke3PVMh\|ryP	M2LodHNCVkeHUh?=
GT3TKB	NGraeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETLXY1KSzVyPUmuN\|U2PDZizszN	Mn;rV2FPT0WU
NB6	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXwfmtUUUN3ME25MlkzOjV7IN88US=>	MVfTRW5ITVJ?
EHEB	M2\qPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPvTWM2OD1zMD6wOlU3KM7:TR?=	M2e4U3NCVkeHUh?=
HEL	NUj4RZhNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHtcldKSzVyPUGwMlQ4PzZizszN	MV\TRW5ITVJ?
ALL-PO	MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTFyLke5N\|gh\|ryP	NWrWemFzW0GQR1XS
TGW	M3LKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkj0TWM2OD1zMT6yPFI5KM7:TR?=	NYDDXo0xW0GQR1XS
BC-3	NFjJbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInwfJFKSzVyPUGyMlEyOzhizszN	NWnSdpRrW0GQR1XS
IA-LM	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\SUVVKSzVyPUGyMlQ1PDVizszN	NHfZO4JUSU6JRWK=
UACC-257	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF{LkmxPVgh\|ryP	MoXPV2FPT0WU
KP-N-YS	NHz4R45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTF{LkmyPFMh\|ryP	MUfTRW5ITVJ?
Raji	M{fIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLRTWM2OD1zMz63OFk4KM7:TR?=	MlraV2FPT0WU
SF539	NGDxT\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWO0VYM4UUN3ME2xN{45PTV5IN88US=>	NE\xTXpUSU6JRWK=
DMS-153	M{P0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3voe2lEPTB;MUSuNFAzQCEQvF2=	NUnLbGJXW0GQR1XS
L-540	NVvBVlZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHu4NJVKSzVyPUG1MlA3PzJizszN	MXfTRW5ITVJ?
MN-60	NVHmWG13T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlSxTWM2OD1zNT6xPVc6KM7:TR?=	MUXTRW5ITVJ?
RPMI-8866	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTF5LkS0OVQh\|ryP	Mlu5V2FPT0WU
NCI-H510A	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnRTWM2OD1zOT6zPVc{KM7:TR?=	M4XvdHNCVkeHUh?=
NB13	M1vEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrFZopKSzVyPUG5MlQ5PzdizszN	NGrndWJUSU6JRWK=
HAL-01	Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XqS2lEPTB;MUmuO\|U1OyEQvF2=	NXPYfJhlW0GQR1XS
NCI-H720	M1fGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2[wd2lEPTB;MkCuNlc{OyEQvF2=	NH;TS\|RUSU6JRWK=
REH	M4jhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{jMSWlEPTB;MkCuOlM2PyEQvF2=	MV7TRW5ITVJ?
KNS-81-FD	NVrHV\|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPVfVBKSzVyPUKzMlE1PiEQvF2=	M3j5U3NCVkeHUh?=
HC-1	NVHVXmZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4P1[mlEPTB;MkSuOVU2OSEQvF2=	Mmj6V2FPT0WU
NCI-H2141	NH60RZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITBfGRKSzVyPUK0Mlc4PTRizszN	MlPiV2FPT0WU
MOLT-4	NWrVXlMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfqTG9TUUN3ME2yOk43PzV\|IN88US=>	NYDTW5VsW0GQR1XS
OMC-1	MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHveW9KSzVyPUK3MlE1OjJizszN	M1izSnNCVkeHUh?=
LC-1F	M371dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;oTWM2OD1{Nz6zNlQ2KM7:TR?=	NG\QVGxUSU6JRWK=
NCI-H1304	M4fuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTJ6LkG2Nlgh\|ryP	NXjzR4RrW0GQR1XS
BC-1	MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\oRmlEPTB;MkiuOlUyKM7:TR?=	MYfTRW5ITVJ?
NCI-H64	NF7nZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFr0dHRKSzVyPUK5MlYzPTNizszN	NGXBenNUSU6JRWK=
MOLT-16	NGXSVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTJ7Lk[yPVIh\|ryP	M1PQenNCVkeHUh?=
U-87-MG	NXPwT2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGHWfZpKSzVyPUOwMlc3PiEQvF2=	MXnTRW5ITVJ?
GAK	Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmfMTWM2OD1\|MT6yOlg3KM7:TR?=	MlrnV2FPT0WU
ES8	MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\OR2FKSzVyPUOyMlEzPTJizszN	M3[1PXNCVkeHUh?=
HCC1599	Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1i3NWlEPTB;M{KuN\|MzPSEQvF2=	MoX0V2FPT0WU
EB-3	NUfSUopRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTN2LkOxNVch\|ryP	M1\qN3NCVkeHUh?=
HCC1187	MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTN3LkiwOVIh\|ryP	NVG4RXdsW0GQR1XS
SK-PN-DW	NVTXbpNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHz1fY1KSzVyPUO2MlE6PDNizszN	Moj4V2FPT0WU
JVM-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV3HbXBvUUN3ME2zO{4zOzN6IN88US=>	M370[3NCVkeHUh?=
HCC2157	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHT2VGFKSzVyPUO3Mlk6PDZizszN	M4D1NnNCVkeHUh?=
A4-Fuk	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUm4fHlDUUN3ME2zPE4yODB7IN88US=>	M4jmSHNCVkeHUh?=
COR-L279	M3P5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLaUI5YUUN3ME20NE4zQDVzIN88US=>	NFzmXGhUSU6JRWK=
DEL	M2r5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFewTIxKSzVyPUSxMlkxQDZizszN	Ml\oV2FPT0WU
NCI-H1395	NWC3RXZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPTdZpKSzVyPUSyMlAyPjNizszN	MlHmV2FPT0WU
MHH-NB-11	NWHOfI83T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7ucJdzUUN3ME20N{4xQDF6IN88US=>	NWWwPYlUW0GQR1XS
NCI-H2107	NYXZN3dDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnP6TWM2OD12Mz60PFQ3KM7:TR?=	NW\RW2N{W0GQR1XS
NEC8	NH3SfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TieWlEPTB;NESuN\|M3KM7:TR?=	M324[XNCVkeHUh?=
COLO-684	NWjzTIg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjkUmNKSzVyPUS2MlIzPThizszN	NEHpbFBUSU6JRWK=
LS-411N	NXL6S5Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTR6LkS3OFgh\|ryP	NEnsfYhUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); PubMed: 23049975 PLoS One Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition. p27 / p21; PubMed: 20145167 Clin Cancer Res Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading. p-FAK / p-STAT3; PubMed: 23721490 BMC Cancer The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive. cleaved caspase 3; PubMed: 20145167 Clin Cancer Res Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.	23049975 20145167 23721490
Growth inhibition assay	IC50; PubMed: 23721490 BMC Cancer 9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.	23721490
Immunofluorescence	SRC / Met; PubMed: 26517812 Oncotarget Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. F-actin / Actinin-4 / Paxillin; PubMed: 31053734 Nat Commun Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions. α-tubulin; PubMed: 26517812 Oncotarget Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.	26517812 31053734
ELISA	TNF-α; PubMed: 17684099 Proc Natl Acad Sci U S A U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate. E-selectin; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM). VCAM-1; PubMed: 31110200 Sci Rep HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).	17684099 31110200

In vivo

Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase autophosphorylation assays: Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research: ^[1]	- Collapse Cell lines: Ba/F3 cell lines Concentrations: ~32 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC) Dosages: 30 mg/kg Administration: Administered via i.p. (Only for Reference)

References

[4] Dargart JL, et al. Antiviral Res. 2012, 95(1), 49-56.

- Collapse

Solubility (25°C)

In vitro	DMSO	98 mg/mL (200.81 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dasatinib SDF

Molecular Weight	488.01
Formula	C₂₂H₂₆ClN₇O₂S
CAS No.	302962-49-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	BMS-354825
Smiles	CC1=NC(=CC(=N1)N2CCN(CCO)CC2)NC3=NC=C(S3)C(=O)NC4=C(Cl)C=CC=C4C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04063124	Suspended	Drug: Dasatinib + Quercetin	Alzheimer Disease	The University of Texas Health Science Center at San Antonio\|Mayo Clinic	February 14 2020	Phase 1\|Phase 2
NCT04155411	Recruiting	Drug: Dasatinib	Dasatinib\|BCR-ABL\|Chronic Myeloid Leukemia	Shenzhen Second People''s Hospital	December 1 2019	Phase 4
NCT04115059	Recruiting	Drug: Dasatinib	Waldenstrom Macroglobulinemia\|DASATINIB	Jorge J. Castillo MD\|Bristol-Myers Squibb\|Dana-Farber Cancer Institute	November 4 2019	Phase 1
NCT03318770	Not yet recruiting	Drug: Dasatinib and blinatumomab	Acute Lymphoblastic Leukemia	Gruppo Italiano Malattie EMatologiche dell''Adulto	December 2018	--
NCT03625388	Recruiting	Drug: Dasatinib	Chronic Myelogenous Leukemia	Hikma Pharmaceuticals LLC	November 5 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
what’s the difference between S1021 and S7782? Which one is better for in vivo studies?
Answer:
Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).
Question 2:
Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?
Answer:
Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Pan Src Inhibitor

Saracatinib (AZD0530) : Pan-Src inhibitor, IC50=2.7-11 nM for c-Src/c-Yes/Fyn/Lyn/Blk/Fgr/Lck.
FDA-approved Src Inhibitor

Bosutinib (SKI-606) : Approved by FDA for Ph+ chronic myelogenous leukemia (CML).
Newest Src Inhibitor

PP1 : Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
Classic Src Inhibitor

KX2-391 : The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Related Src Products

Dasatinib Monohydrate ^New

Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.
Bosutinib (SKI-606)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
KX2-391（Tirbanibulin）

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.
PP1

PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.
PP2

PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
WH-4-023

WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50s of 2 nM and 6 nM in cell-free assays, respectively. Exhibits >300-fold selectivity against p38α and KDR. Also potently inhibits SIK (IC50 values are 10, 22 and 60 nM for SIK 1, 2 and 3 respectively) and displays selectivity over a range of closely related kinases.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.

Choose Your Country or Region

By Signaling Pathways

By product type

Dasatinib